WayPoint Biomedical Receives Strong Upgrade by Respected Research Firm; $7.5 Million Secured for New Medical Records Joint Vent

WayPoint Biomedical, Inc. (Other OTC: WYPH.PK) is
pleased to announce a well-respected firm, TRI-STATE Capital (TSC),
has upgraded their equity rating on WYPH. This strong upgrade comes at
a time when the company is preparing to launch their new high demand
Hangover Free topical patch and further expand the US launch of their
drink spiking detection kit range. The strong upgrade is also due to
WayPoint management securing $7.5 million in initial capital to
manufacture, market, and distribute their new JV's SmartCard-based
Electronic Medical Records healthcare technology on a global scale.
   WayPoint CEO, Dennis Shepherd, states, "We are honored to have a
quality independent research firm review our overall operations,
progress and to provide the resulting upgrade in our stock. This
offers further confirmation to our shareholders that our company is
headed in the right direction". Mr. Shepherd further comments, "Our
upcoming Hangover Free Topical Patch has the potential to quickly
generate several million dollars of sales and we anticipate a strong
revenue surge from our Drink Detective(TM) drink spiking detection
range through our Las Vegas, NV introduction. Las Vegas is a
playground for sexual predators and thieves who use these now
detectable drugs to perpetuate their crimes. We are introducing both a
product and an education/awareness campaign that can help stop this
crime."
   WayPoint has already received orders from two key Canadian Retail
Pharmacy groups for their drink spiking detection kit. The company has
also confirmed requests for over 10,000 units to be distributed
throughout Las Vegas hotels, bars, clubs, nightclubs, and retail
stores. Management anticipates accelerated growth throughout 2006 and
2007 due to a robust product pipeline of innovative new products,
aggressive marketing, and worldwide expansion.
   TSC is noted for their work with, account executives, analysts,
portfolio managers, institutions, venture capital investors,
individual investors and the media. To view the entire independent
research report, please click on the attached URL:
http://www.otclive.com

   About WayPoint Biomedical, Inc.

   WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint
Biomedical Holdings, Inc. (Other OTC:WYPH), is an innovative
biomedical technology firm, specializing in diagnostic tests and
devices for screening and monitoring human health, fitness and
environment. The Company develops and markets cutting-edge disposable
rapid tests that offer both a preliminary diagnostic screen to
specific conditions, along with a future path for consumers, medical
providers, and first responders to follow regarding their health
status or environmental condition. For more information on WayPoint
Biomedical visit www.waypointbiomedical.com,
www.drinkdetectiveusa.com.

   Forward-Looking Statements

   This press release contains forward-looking statements. By their
nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the near future. There are a number
of factors that could cause actual results and developments to differ
materially.